Go to The Journal of Clinical Investigation
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
  • Physician-Scientist Development
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Immunology
    • Metabolism
    • Nephrology
    • Oncology
    • Pulmonology
    • All ...
  • Videos
  • Collections
    • In-Press Preview
    • Resource and Technical Advances
    • Clinical Research and Public Health
    • Research Letters
    • Editorials
    • Perspectives
    • Physician-Scientist Development
    • Reviews
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • In-Press Preview
  • Resource and Technical Advances
  • Clinical Research and Public Health
  • Research Letters
  • Editorials
  • Perspectives
  • Physician-Scientist Development
  • Reviews
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
Regulation of murine NK cell exhaustion through the activation of the DNA damage repair pathway
Maite Alvarez, Federico Simonetta, Jeanette Baker, Antonio Pierini, Arielle S. Wenokur, Alyssa R. Morrison, William J. Murphy, Robert S. Negrin
Maite Alvarez, Federico Simonetta, Jeanette Baker, Antonio Pierini, Arielle S. Wenokur, Alyssa R. Morrison, William J. Murphy, Robert S. Negrin
View: Text | PDF
Research Article Immunology Oncology

Regulation of murine NK cell exhaustion through the activation of the DNA damage repair pathway

  • Text
  • PDF
Abstract

NK cell exhaustion (NCE) due to sustained proliferation results in impaired NK cell function with loss of cytokine production and lytic activity. Using murine models of chronic NK cell stimulation, we have identified a phenotypic signature of NCE, characterized by upregulation of the terminal differentiation marker KLRG1 and by downregulation of eomesodermin and the activating receptor NKG2D. Chronic stimulation of mice lacking NKG2D resulted in minimal NCE compared with control mice, thus identifying NKG2D as a crucial mediator of NCE. NKG2D internalization and downregulation on NK cells have been previously observed in the presence of tumor cells with high expression of NKG2D ligands (NKG2DL) due to the activation of the DNA damage repair pathways. Interestingly, our study revealed that during NK cell activation, there is an increase of MULT1, an NKG2DL, that correlates with an induction of DNA damage. Treatment with the ATM DNA damage repair pathway inhibitor KU55933 (KU) during activation reduced NCE by improving expression of activation markers and genes involved in cell survival, through sustaining NKG2D expression and preserving cell functionality. Importantly, NK cells expanded ex vivo in the presence of KU displayed increased antitumor efficacy in both NKG2D-dependent and -independent mouse models. Collectively, these data demonstrate that NCE is caused by DNA damage and is regulated, at least in part, by NKG2D. Further, the prevention of NCE is a promising strategy to improve NK cell–based immunotherapy.

Authors

Maite Alvarez, Federico Simonetta, Jeanette Baker, Antonio Pierini, Arielle S. Wenokur, Alyssa R. Morrison, William J. Murphy, Robert S. Negrin

×

Figure 6

Inhibition of the ATM DNA damage repair pathway delays NCE by increasing NK cell function and survival, which improve antitumor responses after NK cell adoptive transfer therapy.

Options: View larger image (or click on image) Download as PowerPoint
Inhibition of the ATM DNA damage repair pathway delays NCE by increasing...
Thy1.2 BM-derived cells were cultured in vitro with IL-2 and treated with DMSO or 7.5 μM ATM inhibitor KU on day 4 of culture. Adherent NK cells were collected at different time points of culture. (A) Hierarchical clustering by Euclidean distance analysis of the expression of multiple NK cell markers is shown. (B) The NCE phenotype was evaluated on in vitro activated NK cells measured by Eomes MFI and the total percentage of NKG2D and KLRG1 on gated NK cells. (C) The percentage of Ki67 is shown. (D) BCL2 MFI is shown on gated NK cells. (E) The 20S proteasome activity of NK cells is shown. (F) The percentage of IFN-γ production after NK1.1 stimulation is shown. (G) The percentage of tumor lysis of NK cells against A20 is shown. (H and I) C57BL/6 mice received total body radiation (TBI) at the time of tumor i.v. infusion (H: A20) or 7 days after tumor administration (I: B16F10), followed by allogeneic (H) or syngeneic (I) hematopoietic stem cell transplantation (HCT), along with freshly isolated unstimulated NK cells (fresh NK) or 5 day ex vivo expanded activated NK cells in the presence of vehicle control (aNK) or KU (KU aNK). When indicated, mice received low doses of IL-2 (5 × 104 IU) for 7 days after NK cell administration. Percentage is of in vivo tumor survival of NKG2D-dependent (H: A20) or -independent (I: B16F10) tumor-bearing mice after HCT with adoptive transfer of PBS (control) or NK cells. Data represent 2 or 3 independent experiments done in triplicate (in vitro model) or with 5–8 mice per group (in vivo tumor model) (mean ± SEM). One-way ANOVA (in vitro model) or log-rank test (in vivo tumor model) were used to assess significance (*P < 0.05, **P < 0.01, ***P < 0.001). In tumor models, the significance between control IL-2 and fresh NK and control IL-2 and KU-aNK (black asterisks) as well as between fresh NK and KU-aNK (red asterisks) is shown.

Copyright © 2026 American Society for Clinical Investigation
ISSN 2379-3708

Sign up for email alerts